Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071779 | 1.00 | GABRP (0.34) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29546852 | 0.74 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3266517 | 0.70 | ALDH1A1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3269541 | 0.70 | ALDH1A1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16069934 | 0.69 | GABRP (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16069932 | 0.68 | NOTUM (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29482079 | 0.68 | HTR2C (0.33) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17915849 | 0.68 | PARP1 (0.42) | — | |
| SCHEMBL13247401 | 0.68 | NOTUM (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31314727 | 0.67 | GABRP (0.32) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20250361320-A1 | ANTI-CEACAM5 ANTIBODIES AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250326855-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304716-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2025-07-10 | — | — | US | disclosed |
| US-20250136701-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2025-04-15 | — | — | US | disclosed |
| EP-3972993-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3169368-B1 | LINKERS AND THEIR APPLICATION TOWARDS ADC | MEDSHINE DISCOVERY INC (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-2755642-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | Seattle Genetics, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013055990-A1 | PYRROLOBENZODIAZEPINES AND TARGETED CONJUGATES | SEATTLE GENETICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2558127-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | Seattle Genetics, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130613-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEATTLE GENETICS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| EP-2350080-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | Spirogen Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010043880-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136701-A1 | ANTI-GLYCO-CMET ANTIBODIES AND THEIR USES | CD2BP2, CSGALNACT1, DNTT | GABRP 2221/4885GABRD 2952/4885GABRA1 1847/4885 |
| US-20260056209-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | CCR8, CCR3, CCR1 | GABRP 612/4885GABRD 227/4885GABRA1 448/4885 |
| US-20250326855-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | GABRP 703/4885GABRD 1556/4885GABRA1 1265/4885 |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | GABRP 1376/4885GABRD 1553/4885GABRA1 424/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | GABRP 306/4885GABRD 651/4885GABRA1 285/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | GABRP 1800/4885GABRD 2084/4885GABRA1 2422/4885 |
| US-20250223359-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | GABRP 1142/4885GABRD 1986/4885GABRA1 874/4885 |
| US-20250361320-A1 | ANTI-CEACAM5 ANTIBODIES AND USES THEREOF | EPCAM, CD47, CD44 | GABRP 858/4885GABRD 2102/4885GABRA1 687/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | GABRP 466/4885GABRD 1244/4885GABRA1 1288/4885 |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | EPCAM, CD40, BCR | GABRP 443/4885GABRD 1129/4885GABRA1 487/4885 |
| US-20250304716-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | GABRP 1800/4885GABRD 2084/4885GABRA1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.